Antimicrobial resistance and brain cancer represent two of the most intractable challenges in medicine today, with resistance mechanisms and tumor evolution constantly undermining existing therapies. Stoked Bio aims to discover medicines for these and other hard-to-treat diseases by using a “biology-first” approach to AI-driven drug discovery. The company’s Mosaic platform, a biology-first, AI-assisted solution, integrates phenotypic screening, proprietary training datasets, and generative AI models to streamline the identification of drugs that selectively kill pathogens and cancer cells. The platform represents a distinctive approach for accelerating drug discovery while cutting costs and reducing attrition rates in early development.
In this GEN webinar, Jon Stokes, PhD, and Jeff Skinner, discuss how Stoked Bio’s platform advances the discovery of new antimicrobials and glioblastoma therapies by combining biological insights with cutting-edge computational models. Key takeaways from the webinar include:
- How a biology-first approach to AI drug discovery accelerates the identification of novel compounds for hard-to-treat conditions including drug-resistant infections and glioblastoma.
- How Stoked Bio leverages CDD Vault to translate academic discoveries into a scalable biotech model.
- How Stoked Bio’s Mosaic platform integrates phenotypic screening, proprietary datasets, and generative AI to reduce costs and failures in early drug development.
- How academic-industry collaborations and robust data management streamline efforts to translate lab discoveries to clinically relevant therapeutics.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
